Press release, Helsinki, 20 December 2024 at 9 AM (EET)
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it has received an NBS 5+ system order from Delve Psychiatry, a psychiatric practice based in Las Vegas, Nevada.
The Nexstim NBS 5+ system enables the delivery of both diagnostic and therapeutic applications. The system is FDA-cleared for presurgical mapping of the speech and motor cortices of the brain, and for the treatment of Major Depressive Disorder.
Delve Psychiatry was founded by John Reitano, MD, a University of Pennsylvania trained psychiatrist. The psychiatric practice added TMS to their catalogue of psychiatry services in 2023 and is now acquiring another NBS 5+ system to increase capacity for MDD treatments.
Dr. Reitano, founder of Delve Psychiatry, comments: “We are really pleased with the results we have been achieving for our patients, so we went with the same device.“
Mikko Karvinen, CEO of Nexstim, says: “It has been great to see Dr. Reitano get an excellent start with treating patients using their first NBS 5+ system now followed by ordering a second one. We are happy to have such committed customers that use the best technology and put all of their efforts into improving patients’ quality of life.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com